TABLE 3

Overall Survival Stratified by CP

CP	Factor	Variable	No. of patients^*	Median survival^†	P	Overall survival^†
A (n = 74)	Age (y)	≥65	30 (41)	17.7 (8.7–19.5)	0.32	13.3 (8.7–15.7)
		<65	44 (59)	11.7 (7.3–14.2)
	Sex	Male	54 (73)	13.7 (8–19.1)	0.35
		Female	20 (27)	13.2 (7.7–17.7)
	PVT	Segmental	24 (32)	14.3 (12.0–17.8)	0.78
		Lobar	27 (37)	14.2 (7.3–19.5)
		Main	23 (31)	7.7 (4.6–13.8)
	AFP	>100 mg/dL	27 (37)	7.8 (6.9–15)	0.16
		≤100 mg/dL	47 (63)	15.6 (13.2–20.7)
	Size^‡	≤5 cm	25 (34)	14.2 (11.4–24.0)	0.27
		>5 cm	49 (66)	11.7 (7.8–17.7)
B7 (n = 51)	Age (y)	≥65	24 (47)	6.4 (4.5–8.1)	0.11	6.9 (5.3–10.1)
		<65	27 (53)	7.9 (5.8–13.3)
	Sex	Male	43 (84)	6.9 (5.0–9.1)	0.60
		Female	8 (16)	6.5 (3.4–11.0)
	PVT	Segmental	11 (22)	6.5 (3.4–38)	0.82
		Lobar	17 (33)	6.9 (4.6–13.3)
		Main	23 (45)	7.7 (4.8–11.1)
	AFP	>100 mg/dL	36 (71)	6.4 (4.6–10.4)	0.94
		≤100 mg/dL	15 (29)	7.9 (6.4–14.4)
	Size^‡	≤5 cm	9 (18)	14.4 (6.9–20.1)	0.04
		>5 cm	42 (82)	6.4 (4.8–8.1)
≥B8 (n = 60)	Age (y)	≥65	27 (45)	3.5 (2.5–5.0)	0.34	3.9 (2.9–5.0)
		<65	33 (55)	4.1 (2.9–6.7)
	Sex	Male	51 (85)	3.9 (2.7–5.0)	0.45
		Female	9 (15)	4.1 (2.7–9.5)
	PVT	Segmental	8 (13)	8.4 (1.2–75.2)	0.015
		Lobar	21 (35)	4.4 (2.5–9.7)
		Main	31 (52)	3.4 (2.5–4.6)
	AFP	>100 mg/dL	41 (68)	3.3 (2.3–4.8)	0.09
		≤100 mg/dL	19 (32)	4.8 (4.1–9.5)
	Size^‡	≤5 cm	16 (27)	12.6 (2.3–21.7)	0.01
		>5 cm	44 (73)	3.6 (2.3–4.8)

↵* Data are n followed by percentage in parentheses.
↵† Data are months followed by 95% CI in parentheses.
↵‡ Size of tumor at baseline.